Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03096808 · ClinicalTrials.gov registry record · Phase 2
Adaptive Radiotherapy for Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer and Oropharynx Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 8
- Study locations
NCT03096808 is a Phase 2 study of Head and Neck Cancer and Oropharynx Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 64 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (75% lower). The trial reports 8 study locations across 2 states.
The verdict
NCT03096808, a Phase 2 study of Head and Neck Cancer and Oropharynx Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to demonstrate that adaptive radiotherapy (ART) in head and neck cancer patients are comparable to historical controls in head and neck patients undergoing standard intensity-modulated radiation therapy (IMRT) without ART.
Conditions Studied
Interventions
- RADIATION Adaptive Radiotherapy
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memoral Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Rockville Centre - Rockville Centre
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2021-10-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03096808
The ClinicalTrials.gov registry entry for NCT03096808 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Adaptive Radiotherapy is the first listed.
NCT03096808 reports 8 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03096808 about?
NCT03096808 is a clinical study titled "Adaptive Radiotherapy for Head and Neck Cancer". The purpose of this study is to demonstrate that adaptive radiotherapy (ART) in head and neck cancer patients are comparable to historical controls in head and neck patients undergoing standard intensity-modulated radiation therapy (IMRT) without ART.
What is the current status of trial NCT03096808?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2017-03-15. Estimated completion is 2021-10-22.
What conditions does trial NCT03096808 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer, Hypopharynx Cancer.
What interventions are being tested in trial NCT03096808?
The interventions under investigation include: Adaptive Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT03096808?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03096808 being conducted?
This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.